As a global manufacturer, IDT Biologika undergoes regular inspections by clients and independent regulatory agencies, such as the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA).
IDT Biologika’s advanced production system positions the company among the world’s leading vaccine manufacturing corporations. Pioneering technologies for the production of new vaccines and pharmaceuticals underscores IDT’s commitment to set standards for pharmaceutical production, both now and in the future. IDT Biologika’s focus on customers and operational excellence has earned the company many international awards.
IDT Biologika was awarded a “Highly Commended” status in the category of “Best Contract Manufacturing Organization” at the 14th annual Vaccine Industry Excellence (ViE) Awards, in the course of the virtual World Vaccine Congress 2021. This distinction is the equivalent to second place and illustrates the recognition of our outstanding services as a vaccine specialist. Winners were selected by customer survey. “It was a turbulent year, but the vaccine industry has never before achieved so much in such short time, which is why we want to thank all of you for your contribution,” says the organizer of the World Vaccine Congress on the homepage naming the winners in the various categories.
This year has seen IDT Biologika receive the CMO Leadership Awards in the categories Reliability and Service. One of the most coveted in pharmaceutical contract manufacturing, this award is conferred to contract manufacturing organizations or CMOs around the world in recognition of services they have provided to the pharmaceutical and biopharmaceutical industries. The Outsourced Pharma and Life Science Leader periodicals present the awards each year. The awards show our high level of performance in contract manufacturing and our commitment to our customers’ projects, even in difficult times.
We are proud to have received the PharmaTech Outlook Award as one of the world’s TOP 10 CMOs. Granted every year to the ten most innovative and influential contract manufacturing organizations in the pharmaceutical industry, this award bears witness to the support and commitment that IDT Biologika has given towards developing and manufacturing COVID-19 vaccines together with several partners across the world.
IDT Biologika is honoured with six 2019 CMO Leadership Awards for Capabilities, Compatibility, Expertise, Quality, Reliability and Service in New York, in March 2019. Sponsored by Life Science Leader magazine, the annual awards recognize the top contract manufacturing organizations (CMO) serving the pharmaceutical and biopharmaceutical industries. Winners were evaluated based on a real-world experiental data and feedback from decision makers who work with contract manufacturing suppliers. IDT Biologika was judged by its customers as a top performer among more than 110 CMO’s. The award adds to IDT’s distinguished reputation in the contract services business and celebrates the company’s ongoing commitment to manufacturing excellence.
The World Vaccine Congress held in Washington DC, in April 2019 is one of the leading platforms focused on networking and sharing information on vaccine innovations from research and industry. The two-day event culminated in the evening ViE Award ceremony, which came with a surprise for IDT participants. IDT Biologika received the ViE Award in the category Best Contract Manufacturing organization. This award holds great significance for IDT Biologika. Customers alone vote on which nomination they think a company should win.
The International Society for Pharmaceutical Engineering (ISPE) recognized IDT Biologika with the Facility of the Year Award for facility integration during the FOYA Awards Banquet 2015, in Washington, D.C. The award spotlights companies that set the standard in pharmaceutical facility design, integration and operational excellence.
Completing a major expansion of its vaccines and biologics contract manufacturing facility in Germany, IDT Biologika established highly automated filling and freeze-drying operations, and by this the basis for large scale commercial manufacturing and increased quality of aseptic operations.
